Quintiles Restructures Early Development/Lab Services Division
This article was originally published in The Pink Sheet Daily
Executive Summary
The division has underperformed in 2004, although recent business win trends are “encouraging,” CFO Ratliff says. The contract research and sales organization believes that underlying demand for its services remains strong, particularly in the product development area.
You may also be interested in...
Quintiles Cymbalta Promotion Expenses Ramping Up; Revenue To Follow
The company expects a 500-plus person sales force hired for the Cymbalta launch to cost $6 mil.-$7 mil. a month over the quarter. A $10 mil. milestone to Lilly is also expected to "hit this quarter."
Quintiles Cymbalta Promotion Expenses Ramping Up; Revenue To Follow
The company expects a 500-plus person sales force hired for the Cymbalta launch to cost $6 mil.-$7 mil. a month over the quarter. A $10 mil. milestone to Lilly is also expected to "hit this quarter."
Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.